Company / Free Cash Flow
Ernexa Therapeutics Inc. Free Cash Flow History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$16.2M
FY2025
5-year range
-$21.3M / $1.8M
FY2021-FY2025
Trend
+20.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow has fluctuated over the past 10 years, ranging from -$21M in FY2023 to $2M in FY2020.
Based on SEC 10-K filings.
-$16M in FY2025.
Improved from -$21M to -$16M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow increased 20.7% year-over-year.
- Peak free cash flow was recorded in FY2020.
- Lowest free cash flow in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$16.2M | +20.7% |
| FY2024 | -$20.4M | +4.0% |
| FY2023 | -$21.3M | -1296.5% |
| FY2020 | $1.8M | +148.0% |
| FY2019 | $717.0K | +500.6% |
| FY2018 | -$179.0K | +55.7% |
| FY2017 | -$404.0K | +92.2% |
| FY2016 | -$5.2M | +28.4% |
| FY2015 | -$7.2M | -1242.4% |
| FY2014 | $632.0K | -32.0% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026